Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.60 |
| ▸ | GRB2 | P62993 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355030 | 1.00 | PTPN1 (0.60) | PTPN1GRB2KMT2A | |
| SCHEMBL29872083 | 0.90 | PTPN1 (0.60) | PTPN1GRB2 | |
| SCHEMBL29597069 | 0.90 | PTPN1 (0.52) | PTPN1KMT2A | |
| SCHEMBL23106585 | 0.89 | PTPN1 (0.56) | PTPN1GRB2 | |
| SCHEMBL30653314 | 0.86 | PTPN1 (0.58) | PTPN1GRB2 | |
| SCHEMBL30429101 | 0.85 | KMT2A (0.56) | PTPN1KMT2A | |
| SCHEMBL29417900 | 0.84 | CASP3 (0.57) | PTPN1KMT2A | |
| SCHEMBL8292011 | 0.84 | PTPN1 (0.54) | PTPN1GRB2 | |
| SCHEMBL30386840 | 0.84 | PTPN1 (0.64) | PTPN1GRB2KMT2A | |
| SCHEMBL29462949 | 0.84 | PTPN1 (0.64) | PTPN1GRB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229639-B2 | Camptothecin derivatives | IMMUNOGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229639-B2 | Camptothecin derivatives | TOP2A, TOP2B, PCNA | PTPN1 3831/4885GRB2 2700/4885KMT2A 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.